文献速递免疫规划卫生政策与健康促进

基层医生对带状疱疹疫苗的实践与认知调查

Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
PubMed 文献 · Vaccine · 2018-10-26

仅5%对RZV非常了解,经济障碍是停用ZVL主因。

要点

  • 50%医生将ZVL推荐给50-59岁成人,33%推荐给HIV感染者,超出ACIP推荐。
  • 仅5%医生对RZV非常了解,90%停用ZVL者归因于经济问题。

核心结论

  • 基层医生对ZVL的推荐存在偏离ACIP指南的情况,对RZV认知度低,经济障碍影响接种实施。

研究设计与样本

  • 2016年7-9月对953名基层医生进行网络和邮寄调查,应答率65%(603/923)。

主要发现

  • 50%推荐ZVL给50-59岁成人,33%推荐给HIV感染者,27%推荐给高剂量泼尼松者。
  • 23%(115/490)曾接种ZVL的医生已停止,其中90%归因于经济问题。
  • 仅5%医生对RZV非常了解。

临床怎么用

  • 应加强对基层医生ACIP带状疱疹疫苗接种指南的培训,纠正对禁忌人群的推荐。
  • 推广RZV需考虑经济障碍和接种服务模式差异。

局限性

  • 调查于2016年进行,RZV尚未上市,结果可能不反映当前实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) has routinely recommended zoster vaccine live (ZVL) for adults ≥60 since 2008; only 33% of eligible adults received it by 2016. A recombinant zoster vaccine (RZV) was licensed in 2017 and ACIP recommended in January 2018. Our objectives were to assess among primary care physicians (1) practices and attitudes regarding ZVL and (2) awareness of RZV. METHODS: We administered an Internet and mail survey from July to September 2016 to national networks of 953 primary care physicians. RESULTS: Response rate was 65% (603/923). Ninety-three % of physicians recommended ZVL to adults ≥60, but fewer recommended it to adults ≥60 with a prior history of zoster (88%), adults > 85 (62%) and adults ≥60 on low-dose methotrexate (42%). Several physicians recommended ZVL in ways that are not recommended by ACIP including to adults 50-59 (50%), adults ≥60 with HIV (33%), and adults ≥60 on high dose prednisone (≥20 mg/day) (27%). Nineteen percent of physicians stocked and administered ZVL and did not refer patients elsewhere for vaccination, 37% did not stock and only referred patients to receive it, and 44% both stocked/administered and referred elsewhere. Twenty-three % (n = 115) of physicians who had ever administered ZVL in the office (n = 490) had stopped, citing primarily financial issues (90%). Only 5% were 'very aware' of RZV. CONCLUSIONS: Physicians report not recommending ZVL to certain ACIP-recommended groups, but report recommending it to some groups for which the vaccine should be avoided. Implementation of recommendations for RZV will need to consider financial barriers and the complex patchwork of office-based and pharmacy delivery ZVL has encountered.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hurley LP, Allison MA, Dooling KL, et al. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV). Vaccine. 2018. PMID: 30420121. doi:10.1016/j.vaccine.2018.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。